Jascayd/Nerandomilast Slowed FVC Decline in IPF
Addition of Nerandomilast (Jascayd) to a treatment regimen for patients receiving standard of care therapy for idiopathic pulmonary fibrosis may slow disease progression.
Tag: Boehringer Ingelheim
All
Latest
Jascayd/Nerandomilast Slowed FVC Decline in IPF
Addition of Nerandomilast (Jascayd) to a treatment regimen for patients receiving standard of care therapy for idiopathic pulmonary fibrosis may slow disease progression.
Read More
FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis
The US FDA approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF), the first new therapy approved in more than 10 years for IPF.
Read More
Positive Data for Nerandomilast in IPF/PPF
Boehringer Ingelheim revealed new data from two Phase 3 clinical trials on Nerandomilast, an investigational orally-administered drug candidate for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
Read More
FDA Grants Accelerated Approval to Hernexeos (zongertinib) Certain NSCLC Patients
Boehringer Ingelheim’s zongertinib (Hernexeos) is a kinase inhibitor approved for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).
Read More
Do Transparent Capsule Inhalers Improve Medication Delivery?
Researchers investigated whether transparent capsules in dry powder inhalers improved medication delivery by providing visual feedback to patients.
Read More
Boehringer Ingelheim Caps Patient Out-of-pocket Inhaler Costs at $35 per Month
Starting June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for all Boehringer Ingelheim inhalers, the company says.
Read More
AAFA Applauds Senate Investigation into Asthma Inhaler Pricing
AAFA says the investigation opens an opportunity to address what patients report as the primary reason why people don’t adhere to their asthma treatment: the cost of prescribed asthma medication.
Read More
Yupelri Not Superior to Spiriva in Phase 4 Trial
Theravance Biopharma’s COPD treatment Yupelri was not superior to Boehringer Ingelheim’s Spiriva Handihaler, according to results from a phase 4 study reported by Theravance.
Read More
FDA Accepts sNDA for ILD Drug in Children and Adolescents
The US Food and Drug Administration accepted a supplemental New Drug Application for an expanded indication of ofev (nintedanib) to treat children and adolescents between 6 to 17 years old with fibrosing interstitial lung disease.
Read More
Boehringer Pulmonary Fibrosis Drug Gets FDA Breakthrough Status
Boehringer Ingelheim’s BI 1015550 is a PDE4B inhibitor with the potential to address both pulmonary fibrosis and inflammation associated with progressive fibrosing interstitial lung diseases.
Read More
FDA Approves Pradaxa to Treat VTE in Children Age 3 Months to 12 Years Old
The FDA approved Pradaxa oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days.
Read More
FDA Approves Ofev for Progressive Interstitial Lung Diseases
The US FDA has approved Boehringer Ingelheim’s Ofev (nintedanib) to treat chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.
Read More
Ofev Tagged a Breakthrough Therapy After Positive Ph3 Results
The FDA has granted Ofev (nintedanib) a breakthrough therapy designation for chronic fibrosing interstitial lung disease, according to Boehringer Ingelheim.
Read MoreBoehringer’s Respimat Inhaler Gets Ease of Use Award
The Arthritis Foundation recognized Respimat with its Ease of Use Commendation for products proven to make life easier for people with arthritis and other physical limitations.
Read More
COPD, Asthma, and Pharmacology
Several new pharmacological treatments for COPD and asthma have appeared on the respiratory market in the past year but what are the advantages these new generation pharmaceuticals?
Read MoreNew Boehringer Data Reinforces Ofev Efficacy, Safety for IPF
New analyses presented at ATS 2016 further add to the efficacy and safety profile of Ofev (nintedanib) in idiopathic pulmonary fibrosis (IPF).
Read MoreBoehringer Ingelheim, Propeller Health to Improve Therapy Adherence in COPD, Asthma
Propeller Health and Boehringer Ingelheim are launching a first-of-its-kind commercial partnership to help people living with COPD and asthma better manage their disease.
Read MoreBoehringer Reveals New COPD Data for Stiolto Respimat
Studies showed consistent improvement in lung function across a range of ages using Stiolto compared to tiotropium, olodaterol or placebo.
Read MoreCOPD Treatment Stiolto Respimat Available in US
Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States, according to manufacturer Boehringer Ingelheim Pharmaceuticals.
Read MoreTiotropium Improves Lung Function for Asthma Patients Regardless of Allergic Status
According to five Phase III trials, lung function significantly improved with the addition of tiotropium delivered via the Respimat inhaler compared to placebo, irrespective of underlying allergic status.
Read MoreFDA Accepts NDA Filing for Boehringer’s IPF Drug Nintedanib
Boehringer Ingelheim Pharmaceuticals Inc’s New Drug Application (NDA) for its investigational compound nintedanib has been accepted for filing by the FDA and granted Priority Review designation.
Read MorePradaxa Approved for Treatment of Pulmonary Embolism and DVT
The FDA has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in certain patients, according to Boehringer Ingelheim Pharmaceuticals.
Read More
Tiotropium Effective In Mist or Powder Form for COPD
New research finds that tiotropium can be delivered safely and effectively to COPD patients in mist and traditional dry powder inhalers.
Read More
Investigating Tiotropium as an Asthma Treatment
For asthma patients who remain symptomatic despite current treatment options, clinical trials looking at the effectiveness of an add-on aerosol therapy using tiotropium could provide potential relief.
Read More